Mohamed El-Shazly

Editorial: Artificial intelligence and anti-cancer drugs: advancing discovery, personalization, and precision oncology

It is fitting that the Topic opens with a broad review of the field itself. Nagrami et al. map AI's footprint across the entire anti-cancer drug pipeline -target identification, virtual screening, molecular docking, multi-omic integration, and the still-unresolved question of clinical validation. Their review is a usef...